BIND Biosciences Inc., is a biopharmaceutical company, leveraging its proprietary Medicinal Nanoengineering™ platform to design, engineer and manufacture highly precise best-in-class targeted therapeutics. Founded in 2007, BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010. The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital/Harvard Medical School covering the scientific founders’ work in therapeutic targeted nanoparticles. BIND is backed by a syndicate of top-tier investors including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investment (representing David H. Koch).